Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF). Saracatinib worked as well or better than two approved drugs at reducing tissue scarring in preclinical models of IPF according to the study published in the American Journal of Respiratory and Critical Care Medicine.
Experimental cancer drug could be effective in treating idiopathic pulmonary fibrosis
October 13, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022